- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00005959
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Phase II Trial of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated Intermediate or High Grade Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with rituximab may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of rituximab plus combination chemotherapy in treating patients who have intermediate-grade or high-grade non-Hodgkin's lymphoma.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
OBJECTIVES: I. Determine the rate of complete response and partial response in patients with intermediate or high grade non-Hodgkin's lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). II. Determine the toxicity of this regimen in these patients. III. Determine the disease-free and overall survival, time to response, and time to disease progression in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified according to the number of risk factors (0-2 vs 3-5). Risk factors include age (no greater than 60 vs greater than 60), tumor stage (II vs III or IV), number of extranodal sites (no more than 1 vs more than 1), performance status (0-1 vs 2-4), and serum LDH level (no greater than normal vs greater than normal). Patients receive rituximab IV on day 1; cyclophosphamide, doxorubicin, and vincristine IV on day 3; and oral prednisone on days 3-7. Patients over 60 also receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover (all other patients receive G-CSF as secondary prophylaxis). Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who respond receive 2 more courses. Patients who have no measurable disease after 6 courses receive rituximab IV once weekly for 4 consecutive weeks. This treatment continues every 6 months for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who have measurable disease after 6 courses of chemotherapy receive 2 more courses for a maximum of 8 courses of CHOP, followed by maintenance therapy with rituximab (as described above). Patients are followed every 6 months for 2 years.
PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study.
Type d'étude
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Montgomery, Alabama, États-Unis, 36106
- Montgomery Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Burbank, California, États-Unis, 91505
- Providence Saint Joseph Medical Center - Burbank
-
Rancho Mirage, California, États-Unis, 92270
- Cancer and Blood Institute of the Desert
-
-
Florida
-
Fort Lauderdale, Florida, États-Unis, 33308
- Southeast Florida Hematology-Oncology Group
-
Miami, Florida, États-Unis, 33176
- Oncology-Hematology Group of South Florida
-
Miami Beach, Florida, États-Unis, 33140
- Mount Sinai Comprehensive Cancer Center
-
Pensacola, Florida, États-Unis, 32501
- Hematology-Oncology Associates, PA
-
-
Kansas
-
Hutchinson, Kansas, États-Unis, 67502
- Hutchinson Clinic, P.A.
-
-
Kentucky
-
Crestview Hills, Kentucky, États-Unis, 41017
- Hematology/Oncology Care Inc.
-
-
Maine
-
Scarborough, Maine, États-Unis, 04074
- Maine Center for Cancer Medicine and Blood Disorders
-
-
Maryland
-
Rockville, Maryland, États-Unis, 20850
- Associates in Oncology and Hematology
-
-
Massachusetts
-
Peabody, Massachusetts, États-Unis, 01960
- North Shore Cancer Center
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Henry Ford Hospital
-
Saint Joseph, Michigan, États-Unis, 49085
- Lakeland Medical Center - St. Joseph
-
-
Missouri
-
Rolla, Missouri, États-Unis, 65401
- Bond Clinic
-
Saint Louis, Missouri, États-Unis, 63136
- Midwest Hematology Oncology Consultants, Ltd.
-
-
New Jersey
-
Morristown, New Jersey, États-Unis, 07962
- Hematology Oncology Associates
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87109
- New Mexico Oncology-Hematology
-
-
New York
-
Bronx, New York, États-Unis, 10466
- Our Lady of Mercy Medical Center
-
Brooklyn, New York, États-Unis, 11235
- HemOnCare, P.C.
-
-
North Carolina
-
Hickory, North Carolina, États-Unis, 28603
- N.W. Carolina Oncology & Hematology, P.A.
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45219
- Oncology/Hematology Care, Inc.
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38163
- University of Tennessee, Memphis
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84124
- Intermountain Hematology/Oncology Associates, Inc.
-
-
Vermont
-
Colchester, Vermont, États-Unis, 05446
- Vermont Center for Cancer Medicine, Inc.
-
-
Virginia
-
Richmond, Virginia, États-Unis, 23226
- Hematology & Oncology Associates of Virginia
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS: Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma Stage II, III, or IV disease B-cell where lymphoid cells are CD20 or CD19 positive No mantle cell, lymphoblastic, or peripheral T-cell non-Hodgkin's lymphoma Measurable or evaluable disease No prior treatment for lymphoma No known CNS metastases A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: At least 12 weeks Hematopoietic: Unless documented bone marrow disease: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGOT and SGPT no greater than 3 times upper limit of normal Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No history of severe heart disease, cardiomyopathy, or congestive heart failure LVEF normal by MUGA or echocardiogram Other: Not pregnant or nursing Fertile patients must use effective contraception No active infection as defined by: Clinical syndrome consistent with a viral or bacterial infection (e.g., influenza, upper respiratory infection, urinary tract infection) OR Fever with a clinical site of infection identified OR Microbiologically documented infection, including, but not limited to, bacteremia or septicemia No known HIV positivity No known sensitivity to E. coli derivatives (e.g., asparaginase, human insulin, human growth hormone, interferon alfa-2b) No other prior malignancy within the past 5 years except surgically cured basal or squamous cell skin cancer or carcinoma in situ of the cervix No psychiatric, addictive, or other disorder that may preclude study
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No concurrent biologic therapy except epoetin alfa No white blood cell transfusions Chemotherapy: See Disease Characteristics No concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No concurrent radiotherapy Surgery: At least 2 weeks since prior major surgery Other: No other concurrent investigational therapy No prophylactic antibiotics
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Carol Brannan, BS, BSN, Amgen
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Lymphome diffus à grandes cellules de stade III chez l'adulte
- Lymphome immunoblastique à grandes cellules de stade III de l'adulte
- Lymphome de Burkitt de stade III chez l'adulte
- Lymphome folliculaire de stade IV de grade 3
- Lymphome diffus à grandes cellules de stade IV chez l'adulte
- Lymphome immunoblastique à grandes cellules de stade IV de l'adulte
- Lymphome de Burkitt de stade IV chez l'adulte
- Lymphome folliculaire stade III grade 3
- Lymphome diffus à petites cellules clivées de stade III chez l'adulte
- Lymphome diffus à cellules mixtes adulte de stade III
- Lymphome diffus à petites cellules clivées de stade IV de l'adulte
- Lymphome diffus à cellules mixtes adulte de stade IV
- Lymphome diffus à petites cellules clivées contigu de stade II chez l'adulte
- Lymphome diffus à petites cellules clivées non contigu de stade II de l'adulte
- Lymphome diffus à grandes cellules non contigu de stade II de l'adulte
- Lymphome diffus à cellules mixtes non contigu de stade II de l'adulte
- lymphome folliculaire non contigu de stade II grade 3
- lymphome de Burkitt non contigu chez l'adulte de stade II
- Lymphome immunoblastique à grandes cellules non contigu de stade II de l'adulte
- Lymphome de Burkitt adulte stade II contigu
- Lymphome immunoblastique à grandes cellules contigu de stade II de l'adulte
- lymphome folliculaire contigu de stade II grade 3
- Lymphome diffus à grandes cellules contigu de stade II chez l'adulte
- Lymphome diffus à cellules mixtes adulte de stade II contigu
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Lymphome
- Lymphome non hodgkinien
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Glucocorticoïdes
- Les hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Agents antinéoplasiques, hormonaux
- Agents antinéoplasiques, alkylants
- Agents d'alkylation
- Agonistes myéloablatifs
- Agents antinéoplasiques phytogéniques
- Inhibiteurs de la topoisomérase II
- Inhibiteurs de la topoisomérase
- Agents antinéoplasiques immunologiques
- Antibiotiques, Antinéoplasiques
- Cyclophosphamide
- Rituximab
- Prednisone
- Doxorubicine
- Doxorubicine liposomale
- Vincristine
Autres numéros d'identification d'étude
- CDR0000067940
- AMGEN-GCSF-990756
- NCI-V00-1593
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .